Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ)
CNY 70.74
(-1.61%)
CNY 70.74
(-1.61%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.46 Billion CNY | 16.11% |
| 2022 | 1.24 Billion CNY | 21.59% |
| 2021 | 1.02 Billion CNY | 49.26% |
| 2020 | 688.68 Million CNY | 26.96% |
| 2019 | 542.43 Million CNY | 25.8% |
| 2018 | 431.2 Million CNY | 19.78% |
| 2017 | 360 Million CNY | 6.17% |
| 2016 | 339.1 Million CNY | 17.97% |
| 2015 | 287.43 Million CNY | 12.88% |
| 2014 | 254.65 Million CNY | 16.48% |
| 2013 | 218.63 Million CNY | 2.97% |
| 2012 | 212.32 Million CNY | 11.44% |
| 2011 | 190.53 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 345.81 Million CNY | -3.63% |
| 2024 Q2 | 534.08 Million CNY | 54.44% |
| 2024 Q3 | 539.61 Million CNY | 1.03% |
| 2023 Q2 | 398.91 Million CNY | 39.21% |
| 2023 Q1 | 286.56 Million CNY | 16.69% |
| 2023 FY | 1.45 Billion CNY | 16.11% |
| 2023 Q3 | 419.39 Million CNY | 5.13% |
| 2023 Q4 | 358.85 Million CNY | -14.43% |
| 2022 FY | 1.24 Billion CNY | 21.59% |
| 2022 Q2 | 298.61 Million CNY | -1.11% |
| 2022 Q1 | 301.95 Million CNY | 17.23% |
| 2022 Q4 | 245.58 Million CNY | -39.17% |
| 2022 Q3 | 403.69 Million CNY | 35.19% |
| 2021 FY | 1.02 Billion CNY | 49.26% |
| 2021 Q2 | 255.16 Million CNY | 23.15% |
| 2021 Q3 | 307.98 Million CNY | 20.7% |
| 2021 Q4 | 257.56 Million CNY | -16.37% |
| 2021 Q1 | 207.19 Million CNY | -5.53% |
| 2020 Q4 | 219.33 Million CNY | -5.68% |
| 2020 Q3 | 232.54 Million CNY | 50.91% |
| 2020 FY | 688.68 Million CNY | 26.96% |
| 2020 Q2 | 154.09 Million CNY | 86.31% |
| 2020 Q1 | 82.7 Million CNY | -37.52% |
| 2019 Q4 | 132.36 Million CNY | -16.59% |
| 2019 Q2 | 140.38 Million CNY | 26.49% |
| 2019 Q1 | 110.98 Million CNY | 17.78% |
| 2019 FY | 542.43 Million CNY | 25.8% |
| 2019 Q3 | 158.69 Million CNY | 13.05% |
| 2018 Q3 | 134.86 Million CNY | 19.16% |
| 2018 FY | 431.2 Million CNY | 19.78% |
| 2018 Q4 | 94.23 Million CNY | -30.13% |
| 2018 Q2 | 113.18 Million CNY | 27.28% |
| 2018 Q1 | 88.92 Million CNY | 12.86% |
| 2017 FY | 360 Million CNY | 6.17% |
| 2017 Q4 | 78.78 Million CNY | -19.96% |
| 2017 Q2 | 96.08 Million CNY | 10.83% |
| 2017 Q1 | 86.69 Million CNY | 8.99% |
| 2017 Q3 | 98.43 Million CNY | 2.45% |
| 2016 FY | 339.1 Million CNY | 17.97% |
| 2016 Q1 | 78.59 Million CNY | 0.0% |
| 2016 Q2 | 86.82 Million CNY | 10.47% |
| 2016 Q3 | 94.13 Million CNY | 8.42% |
| 2016 Q4 | 79.54 Million CNY | -15.5% |
| 2015 FY | 287.43 Million CNY | 12.88% |
| 2014 FY | 254.65 Million CNY | 16.48% |
| 2014 Q4 | 62.23 Million CNY | 0.0% |
| 2013 FY | 218.63 Million CNY | 2.97% |
| 2012 FY | 212.32 Million CNY | 11.44% |
| 2011 FY | 190.53 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. | 7.89 Billion CNY | 81.401% |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | 3.36 Billion CNY | 56.392% |
| Blue Sail Medical Co.,Ltd. | 4.92 Billion CNY | 70.214% |
| Andon Health Co., Ltd. | 3.18 Billion CNY | 53.942% |
| Allmed Medical Products Co., Ltd | 2.75 Billion CNY | 46.763% |
| Improve Medical Instruments Co., Ltd. | 644.62 Million CNY | -127.664% |
| Tofflon Science and Technology Group Co., Ltd. | 5.64 Billion CNY | 73.987% |
| Truking Technology Limited | 6.8 Billion CNY | 78.431% |
| Jiangxi Sanxin Medtec Co.,Ltd. | 1.3 Billion CNY | -12.885% |
| Autek China Inc. | 1.73 Billion CNY | 15.519% |
| Intco Medical Technology Co., Ltd. | 6.91 Billion CNY | 78.788% |
| Jiangsu Apon Medical Technology Co., Ltd. | 417.98 Million CNY | -251.109% |
| Winner Medical Co., Ltd. | 8.18 Billion CNY | 82.07% |
| Imeik Technology Development Co.,Ltd. | 2.85 Billion CNY | 48.578% |
| Zhonghong Pulin Medical Products Co., Ltd. | 2.1 Billion CNY | 30.29% |
| Caina Technology Co., Ltd. | 410.47 Million CNY | -257.533% |